Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon Sep 01, 2021 12:05am
222 Views
Post# 33792887

Motley Fool Article ...

Motley Fool Article ...Forget Trillium ... buy these 3 stocks ...

https://www.fool.ca/2021/08/31/forget-trillium-therapeutics-stock-tsxtril-buy-these-pharma-stocks-instead/

--------------------

Knight Therapeutics

Now if you want cheap and strong from your pharma company, look into Knight Therapeutics (TSX:GUD). The company has access to North and Latin American pharmaceutical healthcare products. Yet despite being cheap with a P/E ratio of 11.75, the company has been reporting record revenue again and again.

Most recently, Knight Therapeutics reported a 24% increase in year-over-year revenue, breaking a record in that time. Adjusted EBITDA also increased 23% year over year, but there’s even more growth available to this company.

Part of this growth comes from Health Canada’s approval of its breast cancer therapy. Shares have been growing since the news two months back after falling further and further during the pandemic. Shares are now down 15% in the last year, but up 7% in the last month.

The company remains with a strong balance sheet and a stellar potential upside of 42% as of writing. So this is definitely one Motley Fool investors should consider above Trillium Therapeutics stock.

<< Previous
Bullboard Posts
Next >>